Accelerated Phase Chronic Myelogenous Leukemia Completed Phase 1 Trials for Cytarabine (DB00987)

IndicationStatusPhase
DBCOND0028985 (Accelerated Phase Chronic Myelogenous Leukemia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00357305Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersTreatment
NCT00098423Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesTreatment
NCT000771813-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesTreatment